| pubmed-article:7689953 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7689953 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:7689953 | lifeskim:mentions | umls-concept:C0041370 | lld:lifeskim |
| pubmed-article:7689953 | lifeskim:mentions | umls-concept:C0597304 | lld:lifeskim |
| pubmed-article:7689953 | lifeskim:mentions | umls-concept:C0031586 | lld:lifeskim |
| pubmed-article:7689953 | lifeskim:mentions | umls-concept:C0851285 | lld:lifeskim |
| pubmed-article:7689953 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7689953 | pubmed:dateCreated | 1993-10-6 | lld:pubmed |
| pubmed-article:7689953 | pubmed:abstractText | Cultured human fibroblasts secrete a specific protease that alters extracellular insulin-like growth factor-binding protein-4 (IGFBP-4) structure and function. This enzyme appears to be secreted in a latent form and requires IGFs for activation. To study regulation of the IGFBP-4 protease, we treated normal adult human fibroblasts with various hormones and growth regulatory factors, and collected the human fibroblast-conditioned medium (HFCM) for analysis of IGFBP-4 protease activity. The IGFBP-4 protease assay involved incubation of 50 microliters HFCM with or without 5 nM IGF-II for 6 h at 37 C under cell-free conditions; IGF-activated IGFBP-4 hydrolysis was assessed by Western ligand blotting. In HFCM from cells treated with vehicle, GH, insulin, epidermal growth factor, steroid hormones, or forskolin, IGF-II induced the select loss of detectable IGFBP-4 during the assay. In contrast, IGFBP-4 levels were maintained when HFCM from cells treated with phorbol ester tumor promoters was incubated with IGF-II under cell-free conditions. Hydrolysis of [125I]IGFBP-4 to 18,000 and 14,000 mol wt fragments also was prevented in HFCM from cells treated with phorbol esters. Phorbol esters had no effect on endogenous or exogenous IGFBP-4 proteolysis when added directly to HFCM during the assay, however. Treatment of cells with actinomycin-D or cycloheximide could prevent a phorbol ester-induced block of IGF-dependent IGFBP-4 proteolysis. These data suggest that phorbol ester tumor promoters stimulate human fibroblasts to produce and secrete an inhibitor of the IGFBP-4 proteolytic reaction. Alterations in IGFBP-4 protease activity could affect local IGF action through regulation of IGFBP-4 availability. | lld:pubmed |
| pubmed-article:7689953 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7689953 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7689953 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7689953 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:7689953 | pubmed:issn | 0013-7227 | lld:pubmed |
| pubmed-article:7689953 | pubmed:author | pubmed-author:BaleL KLK | lld:pubmed |
| pubmed-article:7689953 | pubmed:author | pubmed-author:ConoverC ACA | lld:pubmed |
| pubmed-article:7689953 | pubmed:author | pubmed-author:ClarksonJ TJT | lld:pubmed |
| pubmed-article:7689953 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7689953 | pubmed:volume | 133 | lld:pubmed |
| pubmed-article:7689953 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7689953 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7689953 | pubmed:pagination | 1347-51 | lld:pubmed |
| pubmed-article:7689953 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:meshHeading | pubmed-meshheading:7689953-... | lld:pubmed |
| pubmed-article:7689953 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:7689953 | pubmed:articleTitle | Phorbol ester tumor promoters regulate insulin-like growth factor-binding protein-4 proteolysis. | lld:pubmed |
| pubmed-article:7689953 | pubmed:affiliation | Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905. | lld:pubmed |
| pubmed-article:7689953 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7689953 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7689953 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:3487 | entrezgene:pubmed | pubmed-article:7689953 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7689953 | lld:pubmed |
